CY1124148T1 - Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο - Google Patents

Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο

Info

Publication number
CY1124148T1
CY1124148T1 CY20211100232T CY211100232T CY1124148T1 CY 1124148 T1 CY1124148 T1 CY 1124148T1 CY 20211100232 T CY20211100232 T CY 20211100232T CY 211100232 T CY211100232 T CY 211100232T CY 1124148 T1 CY1124148 T1 CY 1124148T1
Authority
CY
Cyprus
Prior art keywords
cell proliferation
diseases associated
treatment
therapeutic agents
undesirable cell
Prior art date
Application number
CY20211100232T
Other languages
English (en)
Inventor
Silvia PEÑUELAS PRIETO
José BASELGA TORRES
Joan SEOANE SUÁREZ
Original Assignee
Fundació Privada Institució Catalana De Recerca I Estudis Avançats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Institució Catalana De Recerca I Estudis Avançats filed Critical Fundació Privada Institució Catalana De Recerca I Estudis Avançats
Publication of CY1124148T1 publication Critical patent/CY1124148T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση βασίζεται στην παρατήρηση ότι η LIF είναι ικανή να ενεργοποιεί την αυτοανανέωση των βλαστικών κυττάρων όγκου στον καρκίνο, συγκεκριμένα τα γλοιώματα, κάτι το οποίο υποδεικνύει ότι η αναστολή της LIF, και γενικά των κυτοκινών τύπου IL-6, μπορεί να χρησιμοποιηθεί σε θεραπευτικές συνθέσεις, για τη θεραπευτική αγωγή ασθενειών που σχετίζονται με ανεπιθύμητο πολλαπλασιασμό. Η εφεύρεση αναφέρεται επίσης σε μια μέθοδο για την ταυτοποίηση ενώσεων ικανών να εμποδίζουν/αναστέλλουν τον πολλαπλασιασμό των βλαστικών κυττάρων, και σε μια in vitro μέθοδο για τη διάγνωση ασθενειών που σχετίζονται με ανεπιθύμητο κυτταρικό πολλαπλασιασμό σε ένα υποκείμενο ή για τον προσδιορισμό της προδιάθεσης ενός υποκειμένου να πάσχει από την εν λόγω ασθένεια που σχετίζεται με ανεπιθύμητο κυτταρικό πολλαπλασιασμό, ή για πρόγνωση του μέσου προσδόκιμου ζωής των υποκειμένων που πάσχουν από τους εν λόγω όγκους.
CY20211100232T 2009-04-03 2021-03-18 Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο CY1124148T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP10713619A EP2414394A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
PCT/EP2010/054499 WO2010115868A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Publications (1)

Publication Number Publication Date
CY1124148T1 true CY1124148T1 (el) 2022-05-27

Family

ID=42342718

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100232T CY1124148T1 (el) 2009-04-03 2021-03-18 Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο

Country Status (23)

Country Link
US (3) US10100112B2 (el)
EP (2) EP3045474B1 (el)
JP (5) JP6207836B2 (el)
KR (6) KR20190093691A (el)
CN (2) CN102574918A (el)
AU (1) AU2010233791B2 (el)
BR (1) BRPI1015369A2 (el)
CA (1) CA2757680C (el)
CY (1) CY1124148T1 (el)
DK (1) DK3045474T3 (el)
EA (1) EA201101450A1 (el)
ES (2) ES2363358B1 (el)
HR (1) HRP20210352T1 (el)
HU (1) HUE054196T2 (el)
IL (1) IL215467A (el)
LT (1) LT3045474T (el)
MX (1) MX336903B (el)
PL (1) PL3045474T3 (el)
PT (1) PT3045474T (el)
SG (2) SG175032A1 (el)
SI (1) SI3045474T1 (el)
WO (1) WO2010115868A2 (el)
ZA (1) ZA201107215B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040063T2 (hu) * 2005-07-19 2019-02-28 Stemgen S P A Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
JP2017507969A (ja) * 2014-03-11 2017-03-23 ゴーダーヴァリ バイオリファイナリーズ リミテッド がん幹細胞標的化合物
WO2016004060A2 (en) * 2014-06-30 2016-01-07 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
JP2017527582A (ja) * 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
AU2016235298B2 (en) 2015-03-23 2021-03-11 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
KR102716931B1 (ko) * 2016-12-19 2024-10-15 펀다시오 프리바다 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠 Lif에 대한 항체 및 이의 용도
AU2019269131B2 (en) * 2018-05-14 2024-02-22 Fundació Privada Institució Catalana De Recerca I Estudis Avançats Antibodies against LIF and dosage forms thereof
JP7520727B2 (ja) * 2018-06-18 2024-07-23 メドイミューン・リミテッド 癌を有する個人における抗ｌｉｆ抗体治療に対する反応を向上させるための方法
KR20210022065A (ko) * 2018-06-18 2021-03-02 메디뮨 리미티드 암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
KR20220019670A (ko) * 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 Il-6 저해제 및 ccr2 저해제를 조합하여 투여하는 것을 특징으로 하는 비뇨기암의 치료제
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
RO114469B1 (ro) 1987-12-15 1999-04-30 Gene Shears Pty Ltd Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
RU2236251C2 (ru) * 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2003218456A1 (en) 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP1576131A4 (en) * 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
KR20110068987A (ko) * 2008-08-29 2011-06-22 제넨테크, 인크. Ｖｅｇｆ-비의존적 종양의 진단 및 치료
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof

Also Published As

Publication number Publication date
KR20200078668A (ko) 2020-07-01
EP3045474A3 (en) 2016-09-28
US10100112B2 (en) 2018-10-16
ES2363358A1 (es) 2011-08-01
EA201101450A1 (ru) 2012-04-30
US20190211095A1 (en) 2019-07-11
LT3045474T (lt) 2021-05-10
SI3045474T1 (sl) 2021-07-30
JP2019006784A (ja) 2019-01-17
CA2757680C (en) 2021-11-02
JP2016040255A (ja) 2016-03-24
JP6207836B2 (ja) 2017-10-04
EP3045474B1 (en) 2021-01-13
JP7197665B2 (ja) 2022-12-27
JP2020090522A (ja) 2020-06-11
US20200385455A1 (en) 2020-12-10
KR20170121319A (ko) 2017-11-01
US20120114671A1 (en) 2012-05-10
WO2010115868A3 (en) 2011-02-03
KR20180079470A (ko) 2018-07-10
KR20120100703A (ko) 2012-09-12
SG10202010568RA (en) 2020-11-27
AU2010233791A1 (en) 2011-11-03
EP3045474A2 (en) 2016-07-20
WO2010115868A2 (en) 2010-10-14
ES2363358B1 (es) 2012-06-21
PT3045474T (pt) 2021-03-22
CA2757680A1 (en) 2010-10-14
KR102373754B1 (ko) 2022-03-15
BRPI1015369A2 (pt) 2021-06-29
ZA201107215B (en) 2012-12-27
KR20190093691A (ko) 2019-08-09
CN107964043A (zh) 2018-04-27
US11999782B2 (en) 2024-06-04
SG175032A1 (en) 2011-11-28
JP2012522756A (ja) 2012-09-27
HUE054196T2 (hu) 2021-08-30
MX2011010425A (es) 2012-03-06
JP2022031742A (ja) 2022-02-22
MX336903B (es) 2016-02-04
ES2864639T3 (es) 2021-10-14
HRP20210352T1 (hr) 2021-05-28
KR20220035978A (ko) 2022-03-22
PL3045474T3 (pl) 2021-08-09
CN102574918A (zh) 2012-07-11
DK3045474T3 (da) 2021-03-22
IL215467A (en) 2016-06-30
AU2010233791B2 (en) 2016-01-21
EP2414394A2 (en) 2012-02-08
IL215467A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
CY1124148T1 (el) Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο
CY1119451T1 (el) Αντισωμα που αναγνωριζει τον ανθρωπινο ανασταλτικο παραγοντα λευχαιμιας (lif) και η χρηση των anti-lif αντισωματων στη θεραπεια παθησεων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο
CY1117604T1 (el) Μια νεα ομαδα αναστολεων του μονοπατιου stat3 και αναστολεων του μονοπατιου καρκινικων βλαστοκυτταρων
CY1126122T1 (el) Αναστολεις πρωτεϊνικης φωσφατασης της τυροσινης
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
CY1119476T1 (el) Αναστολεις της απομεθυλασης ιστονης
CY1120172T1 (el) Αναστολεις κινασων σερινης/θρεονινης
CY1119722T1 (el) Δημιουργια και περιγραφη πληρως ανθρωπινων θεραπευτικων αντισωματων λαμβανομενων μεσω hucal gold ειδικων για ανθρωπινό cd38
BR112018010927A2 (pt) anticorpos multiespecíficos
CY1116681T1 (el) 5-ανιλινοϊμιδαζοπυριδινες και μεθοδοι χρησης
CY1118072T1 (el) Συζευγματα cc-1065 αναλογων και διλειτουργικων αρθρωτων
CR9315A (es) Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia
EA200700321A1 (ru) Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
EA201391208A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ mTOR/JAK
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
CR9365A (es) Compuestos y metodos para la inhibicion de la protein-cinasa raf
ECSP10010510A (es) Compuestos del inhibidor de raf y métodos de uso de los mismos
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
UY36200A (es) Conjunto de biomarcadores específicos para diagnóstico no invasivo de cáncer de hígado
EA201590724A1 (ru) Prdm14 и fam19a4, молекулярные диагностические маркеры для выявления впч-индуцируемых инвазивных раковых заболеваний и предшествующих им поражений высокой степени
RU2014149559A (ru) Селективные ингибиторы недифференцированных клеток